Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus PD-1 inhibitor for first-line unresectable or metastatic MSI-H/dMMR colorectal cancer
ChiCTR2100047576Phase 2Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and PD-1 Monoclonal Antibody in colorectal cancer (CRC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Progression-free survival. Started Jan 2022; status: recruiting.
02
Drugs
bevacizumabPD-1 Monoclonal Antibody
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100047576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047576.